STUDY OBJECTIVES:Suvorexant is an orexin receptor antagonist approved for treating insomnia at a maximum dose of 20 mg. Phase-3 trials evaluated two age-adjusted (non-elderly/elderly) dose-regimes of 40/30 mg and 20/15 mg with the primary focus on 40/30 mg. We report here results from pooled analyses of the 20/15 mg dose-regime, which was evaluated as a secondary objective in the trials. METHODS: Prespecified analysis of pooled data from two identical randomized, double-blind, placebo-controlled, parallel-group, 3-month trials in non-elderly (18-64 years) and elderly (≥ 65 years) patients with insomnia. Patients were randomized to suvorexant 20/15 mg (non-elderly/elderly), suvorexant 40/30 mg (non-elderly/elderly), or placebo; by design, fewer patients were randomized to 20/15 mg. Efficacy was assessed by self-reported and polysomnography (PSG; subset of patients) sleep maintenance and onset endpoints. RESULTS:Suvorexant 20/15 mg (N = 493 treated) was effective compared to placebo (N = 767 treated) on patient-reported and PSG sleep maintenance and onset endpoints at Night-1 (PSG endpoints) / Week-1 (subjective endpoints), Month-1 and Month-3, except for effects on PSG sleep onset at Month-3. Suvorexant 20/15 mg was generally well tolerated, with 3% of patients discontinuing due to adverse events over 3 months vs. 5.2% on placebo. Somnolence was the most common adverse event (6.7% vs. 3.3% for placebo). There was no systematic evidence of rebound or withdrawal signs or symptoms when suvorexant was discontinued after 3 months of nightly use. CONCLUSIONS:Suvorexant 20/15 mg improved sleep onset and maintenance over 3 months of nightly treatment and was generally safe and well tolerated. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov trial registration numbers: NCT01097616, NCT01097629.
RCT Entities:
STUDY OBJECTIVES:Suvorexant is an orexin receptor antagonist approved for treating insomnia at a maximum dose of 20 mg. Phase-3 trials evaluated two age-adjusted (non-elderly/elderly) dose-regimes of 40/30 mg and 20/15 mg with the primary focus on 40/30 mg. We report here results from pooled analyses of the 20/15 mg dose-regime, which was evaluated as a secondary objective in the trials. METHODS: Prespecified analysis of pooled data from two identical randomized, double-blind, placebo-controlled, parallel-group, 3-month trials in non-elderly (18-64 years) and elderly (≥ 65 years) patients with insomnia. Patients were randomized to suvorexant 20/15 mg (non-elderly/elderly), suvorexant 40/30 mg (non-elderly/elderly), or placebo; by design, fewer patients were randomized to 20/15 mg. Efficacy was assessed by self-reported and polysomnography (PSG; subset of patients) sleep maintenance and onset endpoints. RESULTS:Suvorexant 20/15 mg (N = 493 treated) was effective compared to placebo (N = 767 treated) on patient-reported and PSG sleep maintenance and onset endpoints at Night-1 (PSG endpoints) / Week-1 (subjective endpoints), Month-1 and Month-3, except for effects on PSG sleep onset at Month-3. Suvorexant 20/15 mg was generally well tolerated, with 3% of patients discontinuing due to adverse events over 3 months vs. 5.2% on placebo. Somnolence was the most common adverse event (6.7% vs. 3.3% for placebo). There was no systematic evidence of rebound or withdrawal signs or symptoms when suvorexant was discontinued after 3 months of nightly use. CONCLUSIONS:Suvorexant 20/15 mg improved sleep onset and maintenance over 3 months of nightly treatment and was generally safe and well tolerated. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov trial registration numbers: NCT01097616, NCT01097629.
Authors: David Michelson; Ellen Snyder; Erin Paradis; Mary Chengan-Liu; Duane B Snavely; Jill Hutzelmann; James K Walsh; Andrew D Krystal; Ruth M Benca; Martin Cohn; Christopher Lines; Thomas Roth; W Joseph Herring Journal: Lancet Neurol Date: 2014-03-27 Impact factor: 44.182
Authors: Christopher J Winrow; Anthony L Gotter; Christopher D Cox; Scott M Doran; Pamela L Tannenbaum; Michael J Breslin; Susan L Garson; Steven V Fox; Charles M Harrell; Joanne Stevens; Duane R Reiss; Donghui Cui; Paul J Coleman; John J Renger Journal: J Neurogenet Date: 2011-04-08 Impact factor: 1.250
Authors: Hong Sun; William P Kennedy; Darren Wilbraham; Nicole Lewis; Nicole Calder; Xiaodong Li; Junshui Ma; Ka Lai Yee; Susan Ermlich; Eric Mangin; Christopher Lines; Laura Rosen; Jeffrey Chodakewitz; Gail M Murphy Journal: Sleep Date: 2013-02-01 Impact factor: 5.849
Authors: Y Zopf; C Rabe; A Neubert; K G Gassmann; W Rascher; E G Hahn; K Brune; H Dormann Journal: Eur J Clin Pharmacol Date: 2008-07-05 Impact factor: 2.953
Authors: Kelly E Dunn; Andrew S Huhn; Cecilia L Bergeria; Cassandra D Gipson; Elise M Weerts Journal: J Pharmacol Exp Ther Date: 2019-08-07 Impact factor: 4.030
Authors: Thomas C Neylan; Anne Richards; Thomas J Metzler; Leslie M Ruoff; Jonathan Varbel; Aoife O'Donovan; Melinda Sivasubramanian; Terri Motraghi; Jennifer Hlavin; Steven L Batki; Sabra S Inslicht; Kristin Samuelson; Stephen R Morairty; Thomas S Kilduff Journal: Sleep Date: 2020-10-13 Impact factor: 5.849
Authors: Amnon A Berger; Emily R Sottosanti; Ariel Winnick; Joseph Keefe; Elasaf Gilbert; Jamal Hasoon; Michael E Thase; Alan D Kaye; Omar Viswanath; Ivan Urits Journal: Psychopharmacol Bull Date: 2022-02-25